Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

• Status: Completed
• Trial end date: 2015-01-28
• Target enrollment: 0
• Participant gender: All

Summary

Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuhan Corporation
• Treatments: Sarpogrelate

Criteria

Inclusion Criteria:

• person who signed on ICF

• Type 2 diabetic patient who have microalbuminuria or overt proteinuria

• In case of hypertension patients, who keep the same medication steadily over last 4 weeks

Exclusion Criteria:

• patients who have hypersensitivity on sarpogrelate or other salicylic acid

• patients who should keep the antiplatelet agent because of acute cardiac disease or peripheral vein disease

• patients who took other anticoagulant agent within 1 month

• patient who take ACEI OR ARB but not controlled(over 150/100mmHg)

• Type 1 diabetes patients

• Patient who have cardiac or liver problem

• Cr: >1.8mg/dl or GFR: <40ml/min

• malignant tumor patients